CN110573505B - C5-苯胺喹唑啉化合物及其在治疗癌症中的用途 - Google Patents

C5-苯胺喹唑啉化合物及其在治疗癌症中的用途 Download PDF

Info

Publication number
CN110573505B
CN110573505B CN201880027620.0A CN201880027620A CN110573505B CN 110573505 B CN110573505 B CN 110573505B CN 201880027620 A CN201880027620 A CN 201880027620A CN 110573505 B CN110573505 B CN 110573505B
Authority
CN
China
Prior art keywords
triazol
compound
amino
acetamide
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880027620.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110573505A (zh
Inventor
T.格雷库
J.G.凯特勒
M.J.帕克
S.E.皮尔逊
J.M.史密斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN110573505A publication Critical patent/CN110573505A/zh
Application granted granted Critical
Publication of CN110573505B publication Critical patent/CN110573505B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880027620.0A 2017-04-27 2018-04-26 C5-苯胺喹唑啉化合物及其在治疗癌症中的用途 Active CN110573505B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762490859P 2017-04-27 2017-04-27
US62/490859 2017-04-27
PCT/EP2018/060798 WO2018197642A1 (en) 2017-04-27 2018-04-26 C5-anilinoquinazoline compounds and their use in treating cancer

Publications (2)

Publication Number Publication Date
CN110573505A CN110573505A (zh) 2019-12-13
CN110573505B true CN110573505B (zh) 2023-04-11

Family

ID=62091877

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880027620.0A Active CN110573505B (zh) 2017-04-27 2018-04-26 C5-苯胺喹唑啉化合物及其在治疗癌症中的用途

Country Status (13)

Country Link
US (2) US10273227B2 (enExample)
EP (1) EP3615522B1 (enExample)
JP (1) JP7128204B2 (enExample)
KR (1) KR102603153B1 (enExample)
CN (1) CN110573505B (enExample)
AR (1) AR111494A1 (enExample)
AU (1) AU2018259078B2 (enExample)
CA (1) CA3059283A1 (enExample)
ES (1) ES2888298T3 (enExample)
MX (1) MX389244B (enExample)
RU (1) RU2769694C2 (enExample)
TW (1) TWI774758B (enExample)
WO (1) WO2018197642A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3615522B1 (en) * 2017-04-27 2021-08-04 Astrazeneca AB C5-anilinoquinazoline compounds and their use in treating cancer
CN113039204A (zh) * 2018-10-18 2021-06-25 中国抗体制药有限公司 治疗类风湿性关节炎的方法
UY38540A (es) * 2019-01-14 2020-08-31 Pi Industries Ltd Compuestos de fenilamidina 3-sustituida, preparación y uso
EP4146175A1 (en) 2020-05-08 2023-03-15 Genmab A/S Bispecific antibodies against cd3 and cd20
WO2022040341A1 (en) * 2020-08-20 2022-02-24 The Board Of Trustees Of The Leland Stanford Junior University Abscopal therapy for cancer
WO2022053653A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
BR112023004351A2 (pt) 2020-09-10 2023-04-04 Genmab As Método para tratar linfoma folicular em um sujeito humano
EP4210744A1 (en) 2020-09-10 2023-07-19 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CA3192251A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
EP4210743A1 (en) 2020-09-10 2023-07-19 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
WO2023107863A1 (en) * 2021-12-09 2023-06-15 Deciphera Pharmaceuticals, Llc Heterocyclic compounds as kit kinase inhibitors
US20250275978A1 (en) * 2024-03-04 2025-09-04 Cardiff Oncology, Inc. Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1391562A (zh) * 1999-09-21 2003-01-15 阿斯特拉曾尼卡有限公司 用作药物的喹唑啉衍生物
CN1835945A (zh) * 2003-06-17 2006-09-20 阿斯利康(瑞典)有限公司 作为Aurora激酶抑制剂的喹唑啉衍生物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
TWI324154B (enExample) 2001-04-27 2010-05-01 Kyowa Hakko Kirin Co Ltd
US20050171172A1 (en) * 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as PDGFR modulators
MX2007004403A (es) 2004-10-12 2007-04-27 Astrazeneca Ab Derivados de quinazolina.
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US20070106549A1 (en) 2005-11-04 2007-05-10 Stocking Christine A Turnkey aviation budget management
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US20080194557A1 (en) 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
WO2008089310A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
EP2288383A1 (en) 2008-05-14 2011-03-02 Amgen, Inc Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
CN102532042A (zh) 2010-12-30 2012-07-04 上海医药工业研究院 一种芳基脲类化合物、其中间体及其应用
CN102918029B (zh) * 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
CN103254142B (zh) 2013-04-26 2015-10-28 浙江工业大学 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN104130200B (zh) 2014-07-01 2016-04-20 中山大学 一种2-取代苯基-4-芳胺基喹唑啉衍生物及其制备方法和应用
EP3615522B1 (en) * 2017-04-27 2021-08-04 Astrazeneca AB C5-anilinoquinazoline compounds and their use in treating cancer
WO2018197643A1 (en) 2017-04-27 2018-11-01 Astrazeneca Ab Phenoxyquinazoline compounds and their use in treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1391562A (zh) * 1999-09-21 2003-01-15 阿斯特拉曾尼卡有限公司 用作药物的喹唑啉衍生物
CN1835945A (zh) * 2003-06-17 2006-09-20 阿斯利康(瑞典)有限公司 作为Aurora激酶抑制剂的喹唑啉衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthesis, Antitumor Evaluation and Docking Study of Novel 4-Anilinoquinazoline Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors;Guo-Wu Rao等;《ChemMedChem》;20130502;928-933 *

Also Published As

Publication number Publication date
TWI774758B (zh) 2022-08-21
MX2019012847A (es) 2022-01-07
RU2769694C2 (ru) 2022-04-05
WO2018197642A1 (en) 2018-11-01
JP2020517677A (ja) 2020-06-18
EP3615522B1 (en) 2021-08-04
US10829479B2 (en) 2020-11-10
KR20190141203A (ko) 2019-12-23
AR111494A1 (es) 2019-07-17
AU2018259078A1 (en) 2019-10-17
MX389244B (es) 2025-03-20
ES2888298T3 (es) 2022-01-03
AU2018259078B2 (en) 2021-10-07
RU2019136279A3 (enExample) 2021-05-31
TW201904960A (zh) 2019-02-01
KR102603153B1 (ko) 2023-11-15
CA3059283A1 (en) 2018-11-01
US10273227B2 (en) 2019-04-30
US20180312490A1 (en) 2018-11-01
US20190263787A1 (en) 2019-08-29
JP7128204B2 (ja) 2022-08-30
BR112019022229A2 (pt) 2020-05-12
CN110573505A (zh) 2019-12-13
EP3615522A1 (en) 2020-03-04
RU2019136279A (ru) 2021-05-27

Similar Documents

Publication Publication Date Title
CN110573505B (zh) C5-苯胺喹唑啉化合物及其在治疗癌症中的用途
RU2656597C2 (ru) Хиназолиновые ингибиторы активирующих мутированных форм рецептора эпидермального фактора роста
CN116096710A (zh) 用于治疗braf相关疾病和障碍的4-氧代-3,4-二氢喹唑啉酮化合物
CN114364672A (zh) 苯并异噁唑磺酰胺衍生物
AU2011311814B2 (en) Substituted pyridazine carboxamide compounds
EA022087B1 (ru) Морфолинопиримидины и их применение в терапии
JP6139792B2 (ja) タンキラーゼ阻害剤としてのピリド［２，３−ｄ］ピリミジン−４−オン化合物
JP2019518776A (ja) Ｅｇｆｒ阻害剤としてのアニリンピリミジン化合物の結晶
CN105377835A (zh) 酪氨酸蛋白激酶调节剂及其应用方法
CN110546147B (zh) 苯氧基喹唑啉化合物及其在治疗癌症中的用途
BR112019022229B1 (pt) Compostos de anilinoquinazolina c5, composição farmacêutica e uso dos compostos no tratamento do câncer
HK1188216B (en) Substitututed 6-amino-pyridazin-3-yl-carboxamide compounds as protein kinase modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant